To investigate whether expressions of Aur A, BRCA2, SLUG, FBN1, and p53 were associated with clinical pathological characteristics of ovarian cancer patients, we performed immunostaining using antibodies to BRCA2, Aurora-A, SLUG, FBN1 or p53 in a tumor tissue microarray consisting of 150 high-grade ovarian serous carcinomas and 30 normal ovarian tissues. This evidence concerns the gene TP53 and ovarian serous carcinoma.